OneSource Speci.

Which are the latest news on OneSource Speci.?

Why is OneSource Specialty Pharma Ltd falling/rising?

As of 05-Sep, OneSource Specialty Pharma Ltd's stock price is declining, currently at 1,533.70, down 2.54%. The stock has underperformed significantly over the year, facing challenges such as low return on equity and high promoter pledging, contributing to its downward trend.

As of 05-Sep, OneSource Specialty Pharma Ltd's stock price is falling, currently at 1,533.70, which reflects a decrease of 40.0 points or 2.54%. This decline follows a trend reversal after three consecutive days of gains. The stock has underperformed its sector by 1.68% today and has touched an intraday low of Rs 1528, representing a drop of 2.9%.<BR><BR>The company's performance metrics indicate a troubling picture. Year-to-date, the stock has decreased by 15.32%, and over the past year, it has fallen by 18.40%, significantly underperforming the benchmark Sensex, which has only declined by 5.21% in the same period. Additionally, the stock's delivery volume has decreased by 20.15% compared to the five-day average, suggesting a decline in investor participation.<BR><BR>Financially, the company faces challenges with a low return on equity (ROE) of 0.80%, indicating poor management efficiency and profitability. Furthermore, the company's ability to service its debt is weak, as evidenced by a poor EBIT to Interest ratio of 0.29. The stock is also considered to have a very expensive valuation with a high enterprise value to capital employed ratio of 2.6, despite trading at a discount compared to its peers.<BR><BR>Moreover, 37.23% of promoter shares are pledged, which can exert additional downward pressure on the stock price in a declining market. Overall, the combination of poor financial performance, declining investor interest, and high promoter pledging contributes to the stock's current downward trajectory.

What does OneSource Speci. do?

OneSource Specialty Pharma Ltd, a small-cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 449 Cr and a net profit of 25 Cr for June 2026. The company has a market cap of INR 17,366 Cr and a debt-equity ratio of 0.24.

Overview:<BR>OneSource Specialty Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 2007 under the name Inbiopro Solutions Private Limited and later changed its name to Stelis Biopharma Private Limited in 2014 following a Scheme of Amalgamation. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 449 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 25 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 17,366 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.24<BR>- Return on Equity: -1.10%<BR>- Price to Book: 3.02<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Who are the peers of the OneSource Speci.?

OneSource Speci.'s peers include Granules India, Caplin Point Lab, ERIS Lifescience, Astrazeneca Phar, Shilpa Medicare, Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, and Natco Pharma. OneSource Speci. has Below Average management and capital structure risks, with a 1-year return of -19.63%, worse than its peers.

Peers: The peers of OneSource Speci. are Granules India, Caplin Point Lab, ERIS Lifescience, Astrazeneca Phar, Shilpa Medicare, Alivus Life, Cohance Life, Alembic Pharma, Concord Biotech, and Natco Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, Granules India, Caplin Point Lab, Alivus Life, Alembic Pharma, Concord Biotech, and Natco Pharma, while Good management risk is found at ERIS Lifescience, Shilpa Medicare, and Cohance Life. Below Average management risk is attributed to OneSource Speci. Growth is Excellent for OneSource Speci., while Good growth is noted at Shilpa Medicare, and the rest exhibit Below Average growth. Capital Structure is Excellent at Granules India, Caplin Point Lab, Alivus Life, Alembic Pharma, Concord Biotech, and Natco Pharma, while Good capital structure is seen at ERIS Lifescience, and Below Average capital structure is found at OneSource Speci., Shilpa Medicare, and Cohance Life.<BR><BR>Return Snapshot: Shilpa Medicare has the highest 1-year return at 124.50%, while ERIS Lifescience has the lowest at -27.88%. OneSource Speci.'s 1-year return of -19.63% is worse than both of these peers. Additionally, ERIS Lifescience, Astrazeneca Phar, and Natco Pharma have negative six-month returns.

How big is OneSource Speci.?

As of 31st August, OneSource Specialty Pharma Ltd has a market capitalization of 17,366.00 Cr, with Net Sales of 1543.34 Cr and a Net Profit loss of 48.61 Cr for the latest four quarters. Shareholder's Funds are 5,880.58 Cr and Total Assets are 7,550.24 Cr as of March 2025.

As of 31st August, OneSource Specialty Pharma Ltd has a market capitalization of 17,366.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1543.34 Cr. However, it experienced a loss of 48.61 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 5,880.58 Cr and Total Assets were valued at 7,550.24 Cr.

Should I buy, sell or hold OneSource Specialty Pharma Ltd?

Are OneSource Specialty Pharma Ltd latest results good or bad?

OneSource Specialty Pharma Ltd's latest Q1 FY27 results show strong revenue growth and a significant increase in net profit, but concerns remain due to low profit margins and underperformance compared to the broader pharmaceuticals sector. Investors should consider these mixed indicators when evaluating the company's financial health.

OneSource Specialty Pharma Ltd's latest results for Q1 FY27 show a mixed picture. On the positive side, the company reported a net profit of ₹25.00 crore, which is a significant increase of 443.48% compared to the previous quarter. Additionally, revenue grew by 37.20% year-on-year, reaching ₹449.02 crore, marking the highest quarterly sales in the company's recent history. The operating margin improved to 27.47%, reflecting better cost management.<BR><BR>However, despite these positive indicators, there are notable concerns. The profit margins remain significantly lower than historical highs, with the PAT margin at 5.57%, which is a considerable drop from the 23.29% achieved in Q4 FY25. The company's return on equity (ROE) is quite low at 0.80%, indicating challenges in capital efficiency. Furthermore, the stock has underperformed the broader pharmaceuticals sector over the past year, declining 16.07% compared to the sector's gain of 11.43%.<BR><BR>In summary, while OneSource Specialty Pharma has shown strong revenue growth and a return to profitability, persistent profitability challenges and underperformance relative to peers raise caution about its overall financial health. Investors should weigh these factors carefully.

When is the next results date for OneSource Specialty Pharma Ltd?

The next results date for OneSource Specialty Pharma Ltd is July 24, 2026.

The next results date for OneSource Specialty Pharma Ltd is scheduled for July 24, 2026.

How has been the historical performance of OneSource Speci.?

OneSource Speci. has shown significant growth in net sales, increasing from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025, despite facing challenges in profitability, with a profit before tax of -67.07 Cr in March 2025. Total assets rose to 7,550.24 Cr, but cash flow from operating activities remained negative at -67.00 Cr.

Answer:<BR>The historical performance of OneSource Speci. shows significant fluctuations in key financial metrics over the past four years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>OneSource Speci. experienced a dramatic increase in net sales, rising from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025. This surge in total operating income followed a similar trend, moving from 171.92 Cr in March 2024 to 1,444.85 Cr in March 2025. However, the company's total expenditure also escalated, reaching 978.34 Cr in March 2025, up from 260.16 Cr in March 2024. Despite the growth in revenue, the operating profit (PBDIT) improved to 483.98 Cr in March 2025 from a loss of 84.01 Cr in March 2024. Nevertheless, the company reported a profit before tax of -67.07 Cr in March 2025, an improvement from -365.70 Cr in March 2024. The profit after tax also showed a slight recovery, with a loss of -17.28 Cr in March 2025 compared to -365.70 Cr in March 2024. The total assets of OneSource Speci. increased significantly to 7,550.24 Cr in March 2025 from 1,308.61 Cr in March 2024, while total liabilities also rose to 7,550.24 Cr. The cash flow from operating activities remained negative at -67.00 Cr in March 2025, although the net cash inflow improved to 143.00 Cr, indicating a positive shift in cash management. Overall, while OneSource Speci. has shown substantial growth in sales and operating income, it continues to face challenges in profitability and cash flow management.

Is OneSource Speci. overvalued or undervalued?

As of May 7, 2025, OneSource Specialty is considered very expensive and overvalued, with a PE ratio of 168.15 and other high valuation metrics, despite a recent stock performance of 20.62% compared to the Sensex's 3.80%.

As of 7 May 2025, the valuation grade for OneSource Specialty has moved from does not qualify to very expensive. The company is currently overvalued, with a PE ratio of 168.15, a Price to Book Value of 54.64, and an EV to EBITDA ratio of 61.77. These figures indicate a significant premium compared to its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25, and Divi's Laboratories Ltd., with a PE ratio of 79.33.<BR><BR>In comparison to the broader market, OneSource Specialty's stock has shown a strong performance over the past month, returning 20.62% compared to the Sensex's 3.80%. However, despite this recent outperformance, the company's high valuation ratios suggest that it is not justified by its earnings potential, reinforcing the conclusion that it is overvalued in the current market environment.

Who are the top shareholders of the OneSource Speci.?

The top shareholders of OneSource Speci. include Tenshi Pharmaceuticals Private Limited with 17.94%, foreign institutional investors at 18.54%, and mutual funds holding 8.32%. Individual investors represent 12.96%, with Amansa Holdings Private Limited as the largest public shareholder at 3.31%.

The top shareholders of OneSource Speci. include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Tenshi Pharmaceuticals Private Limited holding the highest stake at 17.94%. Additionally, mutual funds collectively hold 8.32% through 10 schemes, while foreign institutional investors (FIIs) own 18.54% across 155 entities. The highest public shareholder is Amansa Holdings Private Limited, which holds 3.31%. Individual investors account for 12.96% of the shareholding.

Has OneSource Speci. declared dividend?

No Dividend History Available